Cargando…
SOCS5 contributes to temozolomide resistance in glioblastoma by regulating Bcl-2-mediated autophagy
Temozolomide (TMZ) is the primary chemotherapeutic drug for treating glioblastoma (GBM); however, the final clinical outcome is considerably limited by the poor response and resistance to TMZ. Although autophagy is thought to be associated with chemotherapy resistance and cancer cell survival, the p...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9342142/ https://www.ncbi.nlm.nih.gov/pubmed/35730472 http://dx.doi.org/10.1080/21655979.2022.2081463 |